MedTrace Logo

A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects

NCT02653872 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2018-02-23

Study results available
· View outcomes & findings →

Summary

This is a phase 1, non-randomized, fixed sequence, 3-period, drug-drug interaction study to assess the pharmacokinetics (PK) of AZD7986 in healthy subjects when administered alone and in combination with multiple doses of verapamil and itraconazole or diltiazem

Conditions

  • Healthy Subjects

Interventions

DRUG

AZD7986

Oral solution, single dose, dilution from concentrate

DRUG

Verapamil

Extended release tablet for oral use

DRUG

Itraconazole

Oral solution

DRUG

Diltiazem

Extended release capsule

Sponsors & Collaborators

Principal Investigators

  • Annelize Koch, MBChB, FFPM · Parexel

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-22
Primary Completion
2016-04-13
Completion
2016-04-13

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02653872 on ClinicalTrials.gov